Analyst Ratings and Insights on Autolus Therapeutics (AUTL)
Autolus Therapeutics, a biopharmaceutical company focused on developing programmed T-cell therapies for cancer treatment, has garnered the attention of analysts in recent months. With a diverse range of opinions from bullish to bearish, analysts have provided valuable insights into the company’s performance and potential.
According to recent data, 4 analysts have shared their opinions on Autolus Therapeutics over the past quarter. The table below summarizes their ratings, offering a comparison between the sentiments expressed in the last 30 days and the preceding months:
| Rating | Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish |
|—————|———|——————|————-|——————|———|
| Total Ratings | 4 | 0 | 0 | 0 | 0 |
| Last 30 Days | 1 | 0 | 0 | 0 | 0 |
| 1 Month Ago | 1 | 0 | 0 | 0 | 0 |
| 2 Months Ago | 2 | 0 | 0 | 0 | 0 |
| 3 Months Ago | 0 | 0 | 0 | 0 | 0 |
The average 12-month price target for Autolus Therapeutics is $9.0, with a high estimate of $10.00 and a low estimate of $8.00. This represents a 9.09% increase from the previous average price target of $8.25.
Analyst actions and evaluations play a crucial role in understanding the market sentiment towards Autolus Therapeutics. Key analysts, such as Gil Blum from Truist Securities and Needham, have made significant changes to their ratings and price targets in recent times:
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|———–|—————–|————–|——–|———————-|——————–|
| Gil Blum | Truist Securities | Raises | Buy | $10.00 | $9.00 |
| Gil Blum | Needham | Maintains | Buy | $9.00 | $9.00 |
| Gil Blum | Needham | Raises | Buy | $9.00 | $8.00 |
| Gil Blum | Needham | Raises | Buy | $8.00 | $7.00 |
Analyzing these analyst ratings alongside financial indicators can provide a comprehensive overview of Autolus Therapeutics’ market position. The company’s financial performance, including market capitalization, revenue trends, net margin, return on equity, return on assets, and debt management, offers additional insights into its operations and profitability.
Understanding how analysts arrive at their ratings is crucial for investors. Analysts predict a company’s future earnings and assess the risk associated with its revenue streams. By attending company meetings, researching financial statements, and communicating with insiders, analysts provide valuable insights for traders.
In conclusion, staying informed about analyst ratings and financial indicators can help investors make well-informed decisions regarding Autolus Therapeutics and other small-cap stocks. By leveraging the expertise of analysts and tracking market trends, investors can navigate the dynamic landscape of the biopharmaceutical industry with confidence.
